Martin Edwards - Sep 30, 2021 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Director
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Sep 30, 2021
Transactions value $
$0
Form type
4
Date filed
10/4/2021, 04:53 PM
Previous filing
Aug 10, 2021
Next filing
Jan 5, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Director Stock Option (Right to Buy) Award $0 +10K $0.00 10K Sep 30, 2021 Common Stock 10K $17.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 12 month period: 1/12th on October 30, 2021, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.